Weight change, metabolic effects, and prolactin levels
were similar
to placebo1
For schizophrenia in adults
In 4- to 6-week clinical trials, mean change in body weight from baseline at 4 weeks was +3.5 lbs for CAPLYTA 42 mg and +2.9 lbs for placebo2
In a long-term study with CAPLYTA,
patients saw an average weight change of1:
Changes in prolactin were similar to placebo in short-term trials and favorable in a long-term, open-label trial2
Mean change from baseline in prolactin2
4- to 6-week trials
Open-label, monotherapy: day 300
Proportion of patients (%) | CAPLYTA (n=406) | Placebo (n=412) | CAPLYTA (n=171) |
---|---|---|---|
Prolactin (ng/mL) | -1.3 | -0.2 | -4.9 |
4- to 6-week trials
Proportion of patients (%) | CAPLYTA (n=406) | Placebo (n=412) |
---|---|---|
Prolactin (ng/mL) | -1.3 | -0.2 |
Open-label, monotherapy: day 300
Open-label, monotherapy: day 300 | CAPLYTA (n=171) |
---|---|
Prolactin (ng/mL) | -4.9 |
≥80% of patients on CAPLYTA remained normal in key metabolic parameters at Day 3002†
Proportion of patients (%) whose key metabolic parameters shifted between normal, low, and high2
Baseline Normal
Proportion of patients (%) | Shifted Normal to Low | Remained Normal | Shifted Normal to High |
---|---|---|---|
Glucose (n=172) | <1% (1/151) | 91% (138/151) | 8% (12/151) |
Insulin (n=168) | 5% (7/134) | 83% (111/134) | 12% (16/134) |
Total cholesterol (n=172) | 12% (14/120) | 80% (96/120) | 8% (10/120) |
LDL cholesterol (n=167) | 3% (4/149) | 93% (139/149) | 4% (6/149) |
Triglycerides (n=172) | 4% (6/155) | 92% (142/155) | 4.5% (7/155) |
Baseline Normal
Proportion of patients (%) | Shifted Normal to Low | Remained Normal | Shifted Normal to High |
---|---|---|---|
Glucose (n=172) | <1% (1/151) | 91% (138/151) | 8% (12/151) |
Insulin (n=168) | 5% (7/134) | 83% (111/134) | 12% (16/134) |
Total cholesterol (n=172) | 12% (14/120) | 80% (96/120) | 8% (10/120) |
LDL cholesterol (n=167) | 3% (4/149) | 93% (139/149) | 4% (6/149) |
Triglycerides (n=172) | 4% (6/155) | 92% (142/155) | 4.5% (7/155) |
†n=number of subjects with data. Baseline is defined as the last non-missing pretreatment measurement.2
Antipsychotic drugs have been reported to cause:
- Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.
Please see additional Important Safety Information, including Boxed Warnings, below.
with schizophrenia and bipolar depression1